key: cord-0429978-zctjkag0
authors: Andeweg, S. P.; Vennema, H.; Veldhuijzen, I.; Smorenburg, N.; Schmitz, D.; Zwagemaker, F.; SeqNeth Molecular surveillance group,; RIVM COVID-19 Molecular epidemiology group,; van Gageldonk-Lafeber, A. B.; Hahne, S. J. M.; Reusken, C.; Knol, M. J.; Eggink, D.
title: Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals
date: 2021-11-24
journal: nan
DOI: 10.1101/2021.11.24.21266735
sha: 5f37b50e0995fa4c75d031df684f188470b42ea4
doc_id: 429978
cord_uid: zctjkag0

The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) break through infection- or vaccine-induced immunity is not well understood. Here, we analyze 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We find evidence for an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14-59 days after complete vaccination compared to 60 days and longer. In contrast to vaccine-induced immunity, no increased risk for reinfection with Beta, Gamma or Delta variants relative to Alpha variant was found in individuals with infection-induced immunity.

Since the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the 52 virus has been slowly but steadily evolving. Although many nucleotide mutations are synonymous, 53 multiple amino acid substitutions in functional domains of the spike protein are observed, some of 54 which with likely impact on transmissibility, disease severity and pre-existing immunity 1 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.24.21266735 doi: medRxiv preprint All four VOCs contain amino acid substitutions in the receptor binding domain (RBD) and N-terminal 63 domain (NTD) of the Spike protein, which are known to be the main target of neutralizing antibodies. 64

Several studies have shown decreased sensitivity of VOCs for convalescent and post-vaccination sera 65 in vitro, with little to no reduction in sensitivity for the Alpha variant, the highest reduction in 66 sensitivity for Beta and to a lesser extent for Gamma and Delta 3-6 . 67 68 These observations and the rapid global spread of first Alpha and later Delta sparked fear for SARS-69

CoV-2 escape from pre-existing immunity and selection of these variants in vaccinated and 70 previously infected individuals. There are indications that the vaccine effectiveness (VE), especially 71 against SARS-CoV-2 infection or mild COVID-19, is lower for the Beta, Gamma and Delta variant 7 . 72

Less is known about the association between the observed VOCs and reinfection. Although an 73 ecological study from the UK did not find an increase in the reinfection rate for the Alpha variant 74 relative to pre-existing variants in the last quarter of 2020 8 , it needs to be determined if increased 75 risk exists of reinfection by the Beta, Gamma, or Delta variants compared to the Alpha variant. 76 77 In January 2021, the COVID-19 vaccination program was rolled out in the Netherlands, first 78 prioritizing health care workers, nursing home residents and the elderly. Current approved vaccines 79 are either based on mRNA (Comirnaty, Spikevax) or on an Adeno-based vector system (Janssen 80 COVID-19 vaccine, Vaxzevria) and are aimed to elicit a spike protein targeted humoral immune 81 response that prevents virus entry and replication 9,10 . As of July 2021, all persons of 12 years and 82 older have been offered COVID-19 vaccination. As of November 2021, 84% of all adults were fully 83 vaccinated and 88% received at least one dose 11 . In the vaccination program in the Netherlands, 84

Comirnaty (BNT162b2, BioNTech/Pfizer) has been used most often and has been offered to all age 85 groups (76.0% of all administered doses). Spikevax (mRNA-1273, Moderna) has been mostly used in 86 long term care facilities, health care workers, high medical risk groups and later also in the general 87 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in information is collected in the national surveillance database and linked to sequence data using a 125 sample identifier supplied during community testing. Sequences from hospital samples (5,893 out of 126 the total 42,662 (13.8%) sequences of the SARS-CoV-2 genomic surveillance samples) and 7,464 of 127 the 36,769 sequenced community samples were excluded as these could not be linked to the 128 national surveillance database for required meta-data. In addition to randomly selected specimens, 129 additional community testing specimens were requested for partially or fully vaccinated individuals 130 as well as for cases with known prior laboratory-confirmed infection. This was done on a 3-weekly 131 basis. This additional sampling resulted in an additional 1,516 cases to be included in the study and 132 allowed for a detailed investigation of infecting variants after vaccination or reinfection. In the 133 current analyses, cases with a sampling date between March 1 and August 31, 2021, were included. 134

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.24.21266735 doi: medRxiv preprint

The majority of isolates were sequenced according to the following representative sequence method 137 (minimal 85.3%), additional detailed protocols are available upon request. Total nucleic acid from 138 combined nasopharyngeal and oropharyngeal swab was extracted using MagNApure 96 (MP96) with 139 total nucleic acid kit small volume (Roche). Total nucleic acid was eluted in 50 μl Tris EDTA buffer. 140 SARS-CoV-2 specific RT-PCR amplification and sequencing was performed using the Nanopore 141 protocol based on the ARTIC v3 amplicon sequencing protocol 23 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in (Table 1) . Of these, 38,261 (5.8%) cases were partly vaccinated, 203 25,933 (3.9%) were fully vaccinated and 10,565 (1.6%) had a known previous infection 204 (Supplementary Figure 1) . Of (partly) vaccinated cases, most received Comirnaty (65.0%), followed 205 by Vaxzevria (19.3%), Janssen COVID-19 vaccine (9.8%) and Spikevax (5.9%). We included data of 206 29,305 samples that were sequenced through the national SARS-CoV-2 surveillance program (Table  207 1). In addition, 1,516 additional samples were sequenced to increase insight in variants present in 208 infections after vaccination and reinfections were included. 209 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in vaccination was less strong and not significant for Beta and Gamma, but still significant for Delta 220 when compared to Alpha (adjusted OR: 1.6 (95% CI: 1.2-2.0); Figure 2 ). We did not find a significant 221 association between previous infection and the Beta, Gamma or Delta variant over Alpha (adjusted 222 OR: 1.4 (95% CI 0.5-3.7); 0.3 (95%CI 0.0-1.9; 1.0 (95%CI 0.6-1.5), respectively; Figure 2 ). The Delta 223 variant was significantly associated with younger age groups, which highlights the importance of 224 adjustment for age group (Supplementary Figure 3) . When only including data from the genomic 225 surveillance (excluding data from additional sampling of vaccinated and reinfected cases), similar 226 odds ratios were found, although not significant anymore for Beta and Gamma due to less power 227 (data not shown). 228 229 When stratified by vaccine type, the association between full vaccination and infection with the 230 Delta variant was significant for Comirnaty and Janssen COVID-19 vaccine, but not for Spikevax and 231

Vaxzevria ( Table 2 ). The association between partial vaccination and the Delta variant was significant 232

for Comirnaty and Vaxzevria but not Spikevax. In addition, we stratified the fully vaccinated by time 233 since vaccination. The association for individuals with less time (14-59 days) between onset and last 234 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.24.21266735 doi: medRxiv preprint dose was higher (OR: 2.3 (95%CI 1.6-3.4)) compared to individuals with 60 days and more (OR: 1.4 235 (95%CI 1.0-2.1)) for the Delta variant. A similar trend was observed for Beta variant and Gamma 236 variant, although with wide confidence intervals (Table 2) were observed as confidence intervals largely overlap. Interestingly, we did not find a significant 245 difference between susceptibility to any of the investigated VOCs among individuals with immunity 246 due to a previous infection compared to naïve individuals. Also when stratified by time between 247 infections no differences are observed (data not shown). Of note is that these analyses do not aim to 248 determine the probability of getting infected after vaccination or previous infection, but rather 249 calculate the likelihood of getting infected with specific VOCs. 250

The association with vaccination status was higher for Beta and Gamma (OR of 3.1 and 2.3, 252 respectively) than for Delta (OR of 1.9), although confidence intervals for Beta and Gamma were 253 wide because of low numbers. This is in line with literature showing lower vaccine effectiveness 254 estimates against infection for Beta and Gamma compared to Delta 7 . An OR for Delta of 1.9 255 implicates a reduction of vaccine effectiveness from 90% to 80%, which has been shown in the 256 UK 3,27 . Current literature still shows high vaccine effectiveness of 90-95% against severe COVID-19 257 for the Delta variant 7,17 , which is reassuring. However, note that with very high vaccine effectiveness, 258 a difference of a factor 1.5-2.0 between two variants could go unnoticed, as it would only mean a 259 decrease of effectiveness of 95 to 92%. 260 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.24.21266735 doi: medRxiv preprint 261 Spike binding and neutralization have been shown to be substantially reduced against Beta, Gamma, 262 and Delta with the largest reduction in neutralization against Beta 4-6 , which is consistent with our 263 results. This observation did not differ for infection-or vaccine-induced immunity, although 264 convalescent sera from mild infections showed lower levels of neutralization potency to VOCs 265 compared to hospitalized cases and vaccinated individuals 4 . However, in Alpha and Beta a reduction 266 was not observed for T-cell-mediated immunity 28 CoV-2 infection 29 . They find a non-delta VE of 97% and a delta VE of 93% one month after 274 vaccination, which means a ratio of 2.3 between non-delta VE and delta VE. Four to five months post 275 vaccination, VE estimates of 67% and 53% for non-delta and delta were observed respectively, a 276 ratio of 1.4. This very well corresponds with our results. Given the broad and sometimes overlapping 277 confidence intervals of these data, however, the differences need to be interpreted with caution. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted November 24, 2021. Odds ratio

The next phase of SARS-CoV-2 surveillance: real-time molecular 315 epidemiology

Tracking SARS-CoV-2 variants

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Emerging SARS-CoV-2 variants of concern evade humoral immune 321 responses from infection and vaccination

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 323 vaccinated serum

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Considerations in boosting COVID-19 vaccine immune responses

Changes in symptomatology, reinfection, and transmissibility associated 329 with the SARS-CoV-2 variant B.1.1.7: an ecological study

Viral targets for vaccines against COVID-19

Four SARS-CoV-2 vaccines induce quantitatively different antibody 334 responses against SARS-CoV-2 variants Short title: Vaccine antibody responses against SARS-335

CoV-2 variants Amsterdam UMC COVID-19 S3/HCW study group

A systematic review of COVID-19 vaccine efficacy and effectiveness 342 against SARS-CoV-2 infection and disease

Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: 345 interim results of a living systematic review

Vaccine effectiveness against SARS-CoV-2 transmission to household 351 contacts during dominance of Delta variant (B.1.617.2), the Netherlands

COVID-19 vaccine effectiveness against hospitalizations and ICU admissions 354 in the Netherlands

Assessment of 357 protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in 358 Denmark in 2020: a population-level observational study

SARS-CoV-2 re-infection risk in Austria

Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome 361 Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study

SARS-CoV-2 infection rates of antibody-positive compared with antibody-364 negative health-care workers in England: a large, multicentre, prospective cohort study 365 (SIREN)

369 sequencing-protocol-v2-bdp7i5rn?version_warning=no. 370 24. GitHub -RIVM-bioinformatics/SARS2seq: SARS2seq is a pipeline designed to process raw 371 FastQ data from targeted SARS-CoV-2 sequencing and generate biologically correct consensus 372 sequences of the SARS-CoV-2 genome

Nextclade: clade assignment, 374 mutation calling and quality control for viral genomes

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist 376 genomic epidemiology

SARS-CoV-2 Delta VOC in Scotland: 378 demographics, risk of hospital admission, and vaccine effectiveness

SARS-CoV-2 variants of concern partially escape humoral but not T-cell 381 responses in COVID-19 convalescent donors and vaccinees

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a 383 large integrated health system in the USA: a retrospective cohort study

Community transmission and viral load kinetics of the SARS-CoV-2 385 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, 386 longitudinal, cohort study

Viral loads of Delta-variant SARS-CoV-2 breakthrough infections 388 after vaccination and booster with BNT162b2

Infection with the SARS-CoV-2 Delta Variant is Associated with Higher 391 Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated 392 Individuals

8%) 3,162 (10.8%) 97 (6.4%)

All rights reserved. No reuse allowed without permission. perpetuity

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.24.21266735 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.24.21266735 doi: medRxiv preprint